Last update Aug. 6, 2017
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
TMC-435 is Simeprevir in Experimental code/s.
Is written in other languages:TMC-435 is also known as
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 62 | % |
Molecular weight | 750 | daltons |
Protein Binding | 99.9 | % |
Tmax | 4 - 6 | hours |
T½ | 10 - 41 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Used alone or in combination with sofosbuvir in the treatment of hepatitis C.
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (slightly elevated molecular weight and very high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into milk, so that although there is disagreement (Thompson 2016), other experts believe that treatment with Simeprevir, on its own or in combination with Sofosbuvir is not contraindicated during breastfeeding (LactMed 2016,
See below the information of these related products: